Urinary biomarkers in lupus nephritis ⁦@RheumNow⁩ and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology! #RNL2023 https://t.co/l1gQgFhviI

Year in Review by Dr. Cush and Dr. Kavanaugh Combo biologic therapy? Phase II study from GI colleagues for UC Guselkumab + golimumab - no additional safety concerns - improved clinical response - extrapolate to rheumatology use? #RNL2023 @RheumNow https://t.co/DirAovm1AX

✅ RheumNow Live 2023 #RNL2023 @RheumNow Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq

TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 ⁦@RheumNow⁩ Safer? No lab monitoring And it works https://t.co/9Woen2q4hZ

Beautiful summary of GPA management by Dr.Carol Langford #RNL2023 ⁦@RheumNow⁩ https://t.co/FCwKN9tovX

PMR lab studies by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Majority of patients will have elevated inflammatory markers. Rapid clinical response to low dose of steroid. https://t.co/AgdIJ5YbOu

Some points to consider in relapsing PMR , by ⁦@anisha_dua⁩ ⁦@RheumNow⁩ #RNL2023 Elevated ESR and CRP rule out GCA. Relapses are common with steroid tapering, especially below 5mg. https://t.co/D17mdly7z5

Long live the GOAT Rx: MTX 🐐🐐 History of usage dating back to 1950 Use 1st-line Optimize dose Supplement folic acid Split dose Give SQ Use in combination therapy Dr Joel Kremer #RNL2023 @RheumNow https://t.co/CCBvQoNHXo

#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023 https://t.co/i0LZoQuK0w

TYK2 signalling Vs JAK signalling summary #RNL2023 https://t.co/0VNBiEc6jq

Approach to pregnancy in patients with PsA , By Dr.Chambers #RNL2023 ⁦@RheumNow⁩ https://t.co/8tSz7qbmQU

Prevalence of PsA in women of reproductive age, By Dr.Chambers #RNL2023 ⁦@RheumNow⁩ https://t.co/hB6QQtz7fw

Dr. Laura Coates on PsA treatment: - Applying treat to target associated with better quality of life - low disease activity is a reasonable target Do you use PROs in managing your PsA pts? Perhaps we should @RheumNow #RNL2023 https://t.co/36n1Cp5jtP

Why do PROs matter? @DrLauraCoates reviewed this slide regarding the increased survival curve in end-stage cancer patients when we monitor PROs. @RheumNow #RNL2023 https://t.co/JfHNBKJGRl

Dr.Robert Spiera approach to GCA #RNL2023 ⁦@RheumNow⁩ https://t.co/ublzYwBbIF